The global GLP-1 Repurposed for Alzheimer’s Market is projected to...
Read More
The global In Vivo CRISPR Gene Editing Cancer Market is projected to expand at a strong CAGR of 15.1% through 2035, driven by sustained demand for tumor-targeted lipid nanoparticle delivery technology, growing research focus on direct targeting of oncogenes such as KRAS and tumor suppressors such as TP53, and continued advancement of base and prime editing technology beyond conventional CRISPR-Cas9 approaches. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises predominantly preclinical and early clinical-stage in vivo gene editing products applied across lung, breast, colorectal, and a broadening set of solid tumor indications.
The market’s strong 15.1% CAGR reflects intensifying biopharmaceutical investment in direct in vivo gene editing as a novel oncology treatment modality, generating structured demand from research institutes and specialized gene therapy centers substantially above discretionary specialty pharmaceutical demand growth, even though current published literature continues to describe direct in vivo CRISPR cancer applications as lacking broad clinical recognition given persistent delivery and tumor specificity hurdles. Sustained research investment in tumor-targeted and stimuli-responsive delivery platforms continues to address the central barrier to clinical translation, while base editing and prime editing technology represent increasingly important alternatives to conventional double-strand-break editing approaches. Coverage extending across multiple delivery platforms, molecular targets, and targeting strategies underscores the breadth of research and development infrastructure now supporting this category.
How does tumor-targeted lipid nanoparticle delivery demand drive the in vivo CRISPR cancer market?
Biopharmaceutical developers continue to advance tumor-targeted lipid nanoparticle and other non-viral delivery platforms to address efficient, tumor-specific in vivo delivery, which remains one of the central barriers to clinical translation for this modality. As delivery technology continues to improve tumor specificity, procurement associated with this approach is expected to outpace growth across the wider gene editing therapeutics sector.
What role does KRAS and TP53 oncogene targeting growth play in market expansion?
Research programs increasingly focus on direct targeting of oncogenes such as KRAS, including the KRAS G12D mutation, alongside tumor suppressor genes such as TP53 and immune-evasion pathways such as PD-L1, sustaining structured demand from research institute and biopharmaceutical developer accounts. Continued research investment in these high-value molecular targets is generating demand that increasingly exceeds levels attributable to earlier, less mechanistically defined editing approaches.
How does base and prime editing technology adoption sustain market growth?
Biopharmaceutical developers increasingly advance base editing and prime editing technology as alternatives to conventional CRISPR-Cas9 double-strand-break editing, sustaining structured demand above conventional editing technology application baselines. Continued technology development in these more precise editing modalities is generating demand from developers pursuing reduced off-target editing risk.
What is driving demand for in vivo CRISPR editing in intratumoral and regional delivery applications?
Developers pursuing intratumoral and other local or regional delivery routes continue to focus this technology on accessible solid tumors, while systemic intravenous delivery remains particularly relevant for metastatic disease, generating incremental demand across both delivery paradigms among clinical-stage biopharmaceutical developers.
How does viral vector delivery platform demand sustain the market?
Biopharmaceutical developers continue to evaluate AAV, adenoviral, and lentiviral delivery systems alongside non-viral platforms for in vivo CRISPR cargo delivery, sustaining structured demand from developers pursuing differentiated delivery efficiency and durability profiles.
Which in vivo CRISPR gene editing cancer market segments are growing fastest?
The fastest-growing segments include tumor-targeted and stimuli-responsive non-viral delivery platforms, KRAS and TP53-directed editing programs, base and prime editing technology, and early feasibility and IND-enabling preclinical development stages.
Key Players
Intellia Therapeutics, Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Prime Medicine, Inc., Editas Medicine, Inc., Verve Therapeutics, Inc., Caribou Biosciences, Inc., Graphite Bio, Inc., Arbor Biotechnologies, Inc., Metagenomi, Inc., Tune Therapeutics, Inc., Chroma Medicine, Inc.
The In Vivo CRISPR Gene Editing Cancer Market’s strong 15.1% CAGR outlook through 2035 is anchored in sustained tumor-targeted lipid nanoparticle delivery demand, growing KRAS and TP53 oncogene targeting activity, and continued base and prime editing technology adoption. Sustained research and development investment from companies including Intellia Therapeutics, Inc., Beam Therapeutics Inc., and Prime Medicine, Inc. confirms the In Vivo CRISPR Gene Editing Cancer Market will sustain strong growth through 2035 as the field advances from a predominantly preclinical current base.
Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.
The global GLP-1 Repurposed for Alzheimer’s Market is projected to...
Read MoreThe global Oral Neuroprotective Alzheimer’s Therapy Market to expand at...
Read MoreThe global siRNA Alzheimer’s Therapy Market is projected to expand...
Read More